BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Moodys
Cipla
Accenture
Deloitte
Chubb
Healthtrust
Chinese Patent Office
Novartis

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,245,911

« Back to Dashboard

Summary for Patent: 6,245,911
Title: Donepezil polycrystals and process for producing the same
Abstract:The present invention provides novel polymorphic crystals (A) to (C) having excellent handling properties and an extremely low content of residual solvent of donepezil used as a precursor for production of donepezil hydrochloride having an excellent action as a medicament, and an industrial process for producing the same. Further, the novel polymorphic crystals (A) to (C) according to the present invention are characterized by the powder X-ray diffraction pattern and/or IR absorption peaks of donepezil represented by the following formula: ##STR1##
Inventor(s): Imai; Akio (Ibaraki, JP), Ichinohe; Toshiyuki (Ibaraki, JP), Endo; Takashi (Ibaraki, JP), Tsurugi; Tomio (Ibaraki, JP), Uemura; Makoto (Ibaraki, JP)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:09/555,807
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 6,245,911

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,245,911

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-336165Dec 05, 1997
PCT Information
PCT FiledDecember 01, 1998PCT Application Number:PCT/JP98/05405
PCT Publication Date:June 17, 1999PCT Publication Number: WO99/29668

International Patents Family Members for US Patent 6,245,911

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 260896 ➤ Subscribe
Germany 69822218 ➤ Subscribe
Denmark 1048653 ➤ Subscribe
European Patent Office 1048653 ➤ Subscribe
Spain 2218869 ➤ Subscribe
Portugal 1048653 ➤ Subscribe
World Intellectual Property Organization (WIPO) 9929668 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
Harvard Business School
Novartis
Mallinckrodt
Medtronic
Dow
Covington
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot